Pennant Group Posts $302.3M in Q3 Revenue, Topping Last Quarter
PNTG sits 98% above its 52-week low of $22.255.
Summary
Pennant Group reported third-quarter revenue of $302.3M, up from $298M in Q2 2026, which itself grew 35.8% year-over-year. The sequential gain extends a steep growth run driven by home health and hospice, with acquisitions and rising debt funding the expansion. Third-quarter net income was $9.6M, up 58.5%, with adjusted EBITDA of $24.7M, up 42.4%, and GAAP diluted EPS of $0.26. Adjusted EPS came in at 35c, which fell short of the IBES estimate of USD 0.36. The stock sits near its 52-week high of $44.24, so the bar for this print was high.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Pennant's Q3 net income was $9.6M, up 58.5%, with adjusted EBITDA of $24.7M, up 42.4%, and GAAP diluted EPS of $0.26.
At the time of this announcement, PNTG was trading at $44.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $22.26 to $44.24. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.